Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Orexo announced that Sun Pharmaceutical Industries have appealed the patent litigation decision issued by the US District Court for the District of New Jersey relating to Orexo's patents protecting ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII) in the US.
read more
The protein supplements market is estimated to grow at a CAGR of 8.18% between 2022 and 2027, increasing by over $10B, according to a report by Technavio.
read more
The global tuberculosis therapeutics market size is expected to reach $2.99B, expanding at a CAGR of 5.09% from 2023 to 2030, according to a report from Research & Markets.
read more
The lactose intolerance treatment market is projected to grow from $28.38B in 2022 to $30.38B in 2023, at a CAGR of 7.1% and is expected to reach $39.18B in 2027, with a CAGR of 6.6%, according to a report by Research & Markets.
read more
The effervescent tablet market size is projected to grow by $4.55B with a CAGR of 5.12% during the forecast period 2021 to 2026, according to a report by Technavio.
read more
Mirum Pharmaceuticals announced that the company will Travere Therapeutics’ bile acid product portfolio, including Cholbam® (cholic acid) and Chenodal® (chenodiol).
read more
The bovine gelatin market is estimated to grow by about $1B from 2022 to 2027, at a CAGR of 8.82%, according to a report by Technavio. Market competition is compelling vendors to adopt various growth strategies, such as promotional activities and spending on advertisements to improve the visibility of their services.
read more
The global probiotics dietary supplements market size is expected to reach $51.84 billion by 2030, registering a CAGR of 14.1% over the forecast periods, according to a report by Research & Markets.
read more
Leading organizations signed and adopted the "Nagasaki Outcomes Statement," which calls for accelerated R&D, access and delivery for neglected tropical diseases (NTDs).
NTDs are a group of 20 preventable and treatable diseases that affect more than 1.6 billion people worldwide, particularly communities in low-income countries.
read more
INW, a manufacturer of nutrition and wellness products, appointed Ray Eby as its chief executive officer.
read more
Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced that the European Commission has granted conditional marketing authorization for LYTGOBI® (futibatinib) monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or ...
read more
Orexo announced that the US District Court for the District of New Jersey ruled in favor of Orexo in its patent litigation against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc. (collectively "Sun") regarding ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (...
read more
Health Canada's approved XCOPRI™ (cenobamate tablets) for Paladin Labs, an Endo operating company. The medicine provides adjunctive therapy to manage partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
read more
The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced.
read more
The market size for prenatal vitamin supplements will grow by $237.81M by 2027 at an 8% CAGR, according to a projection by Technavio.
read more